Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

Phase 2 Not yet recruiting 60 enrolled ProGen. Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy. The treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.

Timeline

Start: 2026-10
Primary completion: 2027-05
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dulaglutide	Peptide	—	Subcutaneous
Subject	PG-102(MG12)	Protein / enzyme biologic	60 mg	Subcutaneous
Subject	PG-102(MG12)	Protein / enzyme biologic	90 mg	Subcutaneous

Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications